Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

Masimo Corporation

Healthcare US MASI

167.685USD
-0.525(0.31%)

Last update at 2025-06-30T18:55:00Z

Day Range

166.54169.06
LowHigh

52 Week Range

75.22169.58
LowHigh

Fundamentals

  • Previous Close 168.21
  • Market Cap6751.43M
  • Volume140254
  • P/E Ratio85.93
  • Dividend Yield-%
  • EBITDA216.50M
  • Revenue TTM1975.90M
  • Revenue Per Share TTM37.35
  • Gross Profit TTM 1058.80M
  • Diluted EPS TTM1.48

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 193.40M 274.38M 263.74M 234.17M 213.78M
Minority interest - - -0.02000M -0.02000M -0.02000M
Net income 143.50M 229.65M 240.30M 196.22M 193.54M
Selling general administrative 657.40M 395.29M 369.06M 314.66M 289.46M
Selling and marketing expenses - - - - -
Gross profit 1058.80M 808.35M 743.07M 629.17M 574.89M
Reconciled depreciation 136.10M 35.62M 29.30M 23.49M 21.13M
Ebit 210.00M 275.82M 255.82M 221.22M 208.89M
Ebitda 346.10M 311.44M 284.18M 244.70M 230.02M
Depreciation and amortization 136.10M 35.62M 28.35M 23.49M 21.13M
Non operating income net other -16.60000M -1.44200M 7.91M 12.95M 5.73M
Operating income 210.00M 275.82M 255.82M 221.22M 208.04M
Other operating expenses 1825.80M 963.33M 888.39M 716.62M 649.82M
Interest expense 25.70M 0.35M 0.34M 0.33M 4.88M
Tax provision 49.90M 44.73M 23.45M 37.95M 20.23M
Interest income 1.80M 0.94M 5.53M 13.92M -
Net interest income -23.90000M 0.58M 5.20M 13.59M -
Extraordinary items - - - - -0.90000M
Non recurring - - -0.47400M - 0.42M
Other items - - - - -
Income tax expense 49.90M 44.73M 23.45M 37.95M 20.23M
Total revenue 2035.80M 1239.15M 1143.74M 937.84M 858.29M
Total operating expenses 848.80M 532.52M 487.72M 407.96M 366.42M
Cost of revenue 977.00M 430.81M 400.68M 308.67M 283.40M
Total other income expense net -16.60000M -1.44200M 7.91M 12.95M 5.31M
Discontinued operations - - - - -
Net income from continuing ops 143.50M 229.65M 240.28M 196.22M 193.54M
Net income applicable to common shares 143.50M 229.65M 240.30M 196.22M 193.54M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 3041.50M 3210.60M 1887.01M 1712.55M 1396.13M
Intangible assets 1204.60M 722.60M 72.50M 73.92M 27.25M
Earning assets - - - - -
Other current assets 99.90M 158.80M 91.03M 102.42M 60.07M
Total liab 1676.70M 1871.70M 336.76M 304.91M 228.25M
Total stockholder equity 1364.80M 1338.90M 1550.24M 1407.66M 1167.87M
Deferred long term liab - 17.10M 28.09M 20.08M 5.26M
Other current liab 222.40M 238.80M 134.86M 118.86M 87.08M
Common stock 0.10M 0.10M 0.06M 0.06M 0.05M
Capital stock 0.10M 0.10M 0.06M 0.06M 0.05M
Retained earnings 1795.80M 1714.30M 1570.86M 1341.23M 1100.49M
Other liab - 246.70M 69.03M 71.08M 40.20M
Good will 407.70M 445.40M 100.33M 103.21M 22.35M
Other assets - 0.30M 202.97M 161.75M 105.30M
Cash 166.00M 202.90M 745.25M 641.45M 567.69M
Cash and equivalents - - - - -
Total current liabilities 563.80M 630.00M 267.74M 233.84M 172.22M
Current deferred revenue 37.40M 80.60M 50.88M 44.94M 25.94M
Net debt 804.00M 772.50M -712.58900M -607.09900M -547.20000M
Short term debt 52.50M 33.80M 6.37M 5.97M 4.65M
Short long term debt 34.30M 15.10M - - -
Short long term debt total 970.00M 975.40M 32.66M 34.35M 20.49M
Other stockholder equity -385.80000M -387.00000M -15.14200M 64.96M 74.04M
Property plant equipment - 402.50M 272.79M 272.51M 219.55M
Total current assets 1231.90M 1308.60M 1238.41M 1101.16M 996.06M
Long term investments 9.90M 13.80M 13.83M 8.00M 6.47M
Net tangible assets - 631.50M 1377.41M 1230.53M 1118.27M
Short term investments - - - 0.00000M 120.00M
Net receivables 421.00M 445.90M 200.76M 141.35M 132.43M
Long term debt 871.70M 941.60M - - -
Inventory 545.00M 501.00M 201.37M 215.95M 115.87M
Accounts payable 251.50M 276.80M 75.63M 64.06M 54.55M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - -0.02000M -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -45.30000M 11.50M -5.53000M 1.41M -6.71800M
Additional paid in capital - - - - -
Common stock total equity - 0.10M 0.06M 0.06M 0.05M
Preferred stock total equity - - - - -
Retained earnings total equity - 1714.30M 1570.86M 1341.23M 1100.49M
Treasury stock - -1169.20000M -767.65500M -638.73600M -526.58000M
Accumulated amortization - - - - -
Non currrent assets other -506.80000M 215.20M 136.53M 114.38M 88.47M
Deferred long term asset charges - - - - 35.97M
Non current assets total 1809.60M 1902.00M 648.60M 611.39M 400.07M
Capital lease obligations 64.00M 72.10M 32.66M 34.35M 20.49M
Long term debt total - 941.60M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1057.70000M -2.60000M 120.00M -120.00000M -26.15200M
Change to liabilities 71.10M 18.10M 42.01M 29.87M 11.96M
Total cashflows from investing activities -1057.70000M -37.52900M -82.78700M -197.68100M -26.15200M
Net borrowings 939.20M 948.50M 948.50M 948.50M -
Total cash from financing activities 520.30M -122.40400M -54.30700M -9.33900M 25.78M
Change to operating activities -59.80000M -8.54600M -17.06000M -9.29000M -7.14400M
Net income 143.50M 229.65M 240.28M 196.22M 193.54M
Change in cash -538.80000M 103.37M 76.93M 15.43M 237.16M
Begin period cash flow 748.40M 645.00M 568.08M 552.64M 315.48M
End period cash flow 209.60M 748.38M 645.00M 568.08M 552.64M
Total cash from operating activities 29.50M 264.75M 210.96M 221.64M 239.53M
Issuance of capital stock 8.10M 23.24M 58.42M 28.34M 44.75M
Depreciation 136.10M 35.62M 29.30M 23.49M 21.13M
Other cashflows from investing activities -1004.90000M -2.60000M -130.23800M -9.30600M -9.02600M
Dividends paid - - - - -
Change to inventory -155.90000M 13.49M -94.43400M -21.25700M -1.88500M
Change to account receivables -138.50000M -60.79900M -2.22900M -23.58000M 10.83M
Sale purchase of stock -401.50000M -128.91700M -110.54000M -37.55500M -18.47800M
Other cashflows from financing activities 1049.10M -16.72800M -2.19100M -0.12300M -0.49000M
Change to netincome 10.20M 30.83M 37.90M 34.31M 19.65M
Capital expenditures 56.30M 34.93M 79.96M 72.49M 22.68M
Change receivables -138.50000M -60.79900M -2.22900M -23.58000M 10.83M
Cash flows other operating -38.50000M -17.17300M -41.85900M -17.41200M -15.70100M
Exchange rate changes - - - - -
Cash and cash equivalents changes -507.90000M 104.82M 73.87M 14.62M 239.16M
Change in working capital -261.80000M -31.34500M -96.51600M -32.37500M 7.22M
Stock based compensation 47.70M 44.62M 42.23M 39.23M 27.42M
Other non cash items 3.30M 1.29M 0.64M 1.04M -1.50600M
Free cash flow -26.80000M 229.82M 131.01M 149.15M 216.84M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MASI
Masimo Corporation		 -0.525 0.31% 167.69 85.93 40.00 3.56 5.35 3.96 34.24
ABT
Abbott Laboratories		 1.08 0.80% 135.46 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 0.61 0.15% 394.16 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 0.96 1.12% 86.98 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 0.77 0.72% 107.30 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

Masimo Corporation

52 Discovery, Irvine, CA, United States, 92618

Key Executives

Name Title Year Born
Mr. Joseph E. Kiani Founder, CEO & Chairman 1965
Mr. Micah Young Exec. VP of Fin. & CFO 1979
Mr. Bilal Muhsin Chief Operating Officer 1981
Mr. Thomas Samuel McClenahan Exec. VP, Gen. Counsel & Corp. Sec. 1973
Mr. Tao Leopold Levy Exec. VP of Bus. Devel. 1974
Mr. Yongsam Lee Exec. VP & Chief Information Officer 1965
Dr. Steven J. Barker Chairman of Scientific Advisory Board & Chief Science Officer 1945
Mr. Eli Kammerman VP of Bus. Devel. & Investor Relations NA
Mr. Jon Coleman Pres of Worldwide Sales, Professional Services & Medical Affairs 1964
Mr. Anand Sampath Exec. VP of Operations & Clinical Research 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.